A psychiatrist whose failure to disclose the drug's corporate income contributed to a furor over conflicts of interest in research biomedical has just received its first national Institutes of Health grant (NIH) in 3 years.
lax reporting of Charles Nemeroff of $ 1.2 million less in payments from pharmaceutical companies to his employer, Emory University, and similar payments to other academic psychiatrists prompted a Senate inquiry 07. Nemeroff resigned as chairman of psychiatry at Emory, and the NIH suspended a grant of $ 9 million he held for a study of depression. In December 08, Emory was forbidden to apply for NIH funding for 2 years.
A year later, Nemeroff moved to the University of Miami Miller School of Medicine in Florida. This has prompted concerns because the ban on Emory NIH grants did not move with him. (Fueling the flames was a telephone call in which the National Institutes of Mental Health (NIMH) Director Thomas Insel apparently assured the University of Miami medical school dean that Nemeroff could seek NIH funding if it has moved.)
NIH requested input on how to handle this situation in a revision of its rules of conflict of interest, but in the final rules issued last summer, he has not addressed specifically.
Now Nemeroff is back in the lap of researchers funded by the NIH. According to the NIH grants database, it received a $ 401.675 per year, 5-year R01 grant from NIMH to study "psychobiological risk factors for PTSD [post-traumatic stress disorder]." The study examines the genetic risk factors and does not appear to involve testing drugs.
The prohibition of 2 years by Emory would have expired anyway. But Paul Thacker, a former staff member for Senator Chuck Grassley (R-IA) who led the Senate inquiry, said NIH itself had the power to impose a ban more. "It shows they are not really serious about the problem," said Thacker.
0 Komentar